Men with prostate cancer may have genomic defects that can be targeted with recently FDA approved PARP Inhibitor medications. All men should undergo genomic testing.
Men with prostate cancer may have genomic defects that can be targeted with recently FDA approved PARP Inhibitor medications. All men should undergo genomic testing.